gentamicin has been researched along with Ductus Arteriosus, Patent in 18 studies
Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.
Ductus Arteriosus, Patent: A congenital heart defect characterized by the persistent opening of fetal DUCTUS ARTERIOSUS that connects the PULMONARY ARTERY to the descending aorta (AORTA, DESCENDING) allowing unoxygenated blood to bypass the lung and flow to the PLACENTA. Normally, the ductus is closed shortly after birth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Birth weight, the 10-minute Apgar score and gentamicin were particularly associated with acute kidney injuries in our cohort." | 7.91 | Birth weight, Apgar scores and gentamicin were associated with acute kidney injuries in VLBW neonates requiring treatment for patent ductus arteriosus. ( Aygün, A; Ebrahimi-Fakhari, D; Gortner, L; Meyer, S; Poryo, M; Wagenpfeil, G; Wissing, A; Zemlin, M, 2019) |
| "Birth weight, the 10-minute Apgar score and gentamicin were particularly associated with acute kidney injuries in our cohort." | 3.91 | Birth weight, Apgar scores and gentamicin were associated with acute kidney injuries in VLBW neonates requiring treatment for patent ductus arteriosus. ( Aygün, A; Ebrahimi-Fakhari, D; Gortner, L; Meyer, S; Poryo, M; Wagenpfeil, G; Wissing, A; Zemlin, M, 2019) |
| "To evaluate the risk of nonsteroidal anti-inflammatory drug (NSAID) therapy-associated acute kidney injury (AKI) among neonates diagnosed with patent ductus arteriosus (PDA) who are treated with gentamicin." | 3.85 | Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin. ( Balch, A; Constance, JE; Korgenski, EK; Reith, D; Sherwin, CMT; Stockmann, C; Thorell, EA; Ward, RM, 2017) |
| "Term neonates with unrepaired CHD who received gentamicin for empiric treatment of sepsis were identified over a 3-year period." | 3.78 | Use of 4-mg/kg/24-hour empiric aminoglycoside dosing in preoperative neonates with congenital heart disease. ( Moffett, BS; Rossano, JW, 2012) |
| "Gentamicin clearance was decreased in the patent ductus arteriosus group vs." | 2.68 | Gentamicin pharmacokinetics in neonates with patent ductus arteriosus. ( Carlos, RQ; Gal, P; Ransom, JL; Schall, SA; Smith, M; Williams, BS, 1997) |
| "Gentamicin was given to more infants with hsPDA than to those without hsPDA (89." | 1.72 | Relationship between Gentamicin Administration and Ductal Patency in Very Low Birth Weight Infants. ( Cakir, U; Tayman, C, 2022) |
| "Rates of patent ductus arteriosus (PDA) and infection are high in preterm infants." | 1.56 | Standard-dose gentamicin does not increase risk of patent ductus arteriosus. ( Akaike, T; Kishibuchi, A; Minamisawa, S, 2020) |
| "Here is a case of a female with patent ductus arteriosus, who was apparently in quite good state of health and gave birth to six offsprings without herself having any problem." | 1.48 | Patent Ductus Arteriosus with Infective Vegetations in Grandmultipara. ( Siddiqa, A; Sohail, N, 2018) |
| "All VLBW infants examined for hearing impairment were included and data were retrieved retrospectively and analyzed for neonatal risk factors using logistic regression." | 1.46 | Prevalence and independent risk factors for hearing impairment among very low birth weight infants. ( Chiang, MC; Chu, SM; Fu, RH; Hsu, JF; Lien, R; Wang, CH; Yang, CY, 2017) |
| "However, the presence of a patent ductus arteriosus, concomitant non-steroidal anti-inflammatory drug use, ≥1 positive blood cultures, low birth weight and higher severity of illness and risk of mortality scores were associated with an increased risk of nephrotoxicity." | 1.43 | A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates. ( Balch, AH; Constance, JE; Korgenski, EK; Linakis, MW; Roberts, JK; Sherwin, CM; Spigarelli, MG; Stockmann, C; Ward, RM, 2016) |
| "Pretreatment with indomethacin and N-(G)-nitro-L-arginine methyl ester did not prevent gentamicin-induced DA relaxation." | 1.40 | Aminoglycoside-mediated relaxation of the ductus arteriosus in sepsis-associated PDA. ( Brown, N; Clark, RH; Cotton, RB; Ehinger, NJ; Goettel, JA; Paria, BC; Poole, SD; Reese, J; Rojas, MA; Shelton, EL; Slaughter, JC; Vucovich, MM; Wynn, JL, 2014) |
| " A 10-percent difference of gentamicin pharmacokinetic parameters between PDA and CDA has been reported; but its implications are unclear." | 1.31 | Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus. ( Lafeber, HN; Proost, JH; Stevens, R; Touw, DJ; van Weissenbruch, MM, 2001) |
| "We developed a simplified gentamicin dosing protocol for all neonates using a loading dose and once-daily dosing that would have an equal or lower incidence of toxicity and an equal or improved effectiveness compared with a regimen with no loading dose that included use of divided daily dosing." | 1.30 | Once-daily gentamicin dosing in newborn infants. ( Cohen, RS; Glasscock, GF; Kim, EH; Lundergan, FS, 1999) |
| "The effect of patent ductus arteriosus (PDA) and its therapy on the pharmacokinetic disposition of gentamicin in very low birth weight neonates was studied." | 1.27 | Effect of patent ductus arteriosus on gentamicin pharmacokinetics in very low birth weight (less than 1,500 g) babies. ( Aldrich, M; Angelus, P; Johnson, JD; Kelly, HW; Watterberg, KL, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Cakir, U | 1 |
| Tayman, C | 1 |
| Constance, JE | 2 |
| Reith, D | 1 |
| Ward, RM | 2 |
| Balch, A | 1 |
| Stockmann, C | 2 |
| Korgenski, EK | 2 |
| Thorell, EA | 1 |
| Sherwin, CMT | 1 |
| Siddiqa, A | 1 |
| Sohail, N | 1 |
| Aygün, A | 1 |
| Poryo, M | 1 |
| Wagenpfeil, G | 1 |
| Wissing, A | 1 |
| Ebrahimi-Fakhari, D | 1 |
| Zemlin, M | 1 |
| Gortner, L | 1 |
| Meyer, S | 1 |
| Kishibuchi, A | 1 |
| Akaike, T | 1 |
| Minamisawa, S | 1 |
| Vucovich, MM | 1 |
| Cotton, RB | 2 |
| Shelton, EL | 1 |
| Goettel, JA | 1 |
| Ehinger, NJ | 1 |
| Poole, SD | 1 |
| Brown, N | 1 |
| Wynn, JL | 1 |
| Paria, BC | 1 |
| Slaughter, JC | 1 |
| Clark, RH | 1 |
| Rojas, MA | 1 |
| Reese, J | 2 |
| Balch, AH | 1 |
| Linakis, MW | 1 |
| Roberts, JK | 1 |
| Sherwin, CM | 1 |
| Spigarelli, MG | 1 |
| Wang, CH | 1 |
| Yang, CY | 1 |
| Lien, R | 1 |
| Chu, SM | 1 |
| Hsu, JF | 1 |
| Fu, RH | 1 |
| Chiang, MC | 1 |
| Veldman, A | 1 |
| Shah, L | 1 |
| Vucovich, M | 1 |
| Mittal, SR | 1 |
| Maheshwari, M | 1 |
| Kent, AL | 1 |
| Brown, L | 1 |
| Broom, M | 1 |
| Broomfield, A | 1 |
| Dahlstrom, JE | 1 |
| Moffett, BS | 1 |
| Rossano, JW | 1 |
| Williams, BS | 1 |
| Ransom, JL | 1 |
| Gal, P | 1 |
| Carlos, RQ | 1 |
| Smith, M | 1 |
| Schall, SA | 1 |
| van den Anker, JN | 1 |
| Kearns, GL | 1 |
| Lundergan, FS | 1 |
| Glasscock, GF | 1 |
| Kim, EH | 1 |
| Cohen, RS | 1 |
| Touw, DJ | 1 |
| Proost, JH | 1 |
| Stevens, R | 1 |
| Lafeber, HN | 1 |
| van Weissenbruch, MM | 1 |
| Watterberg, KL | 1 |
| Kelly, HW | 1 |
| Johnson, JD | 1 |
| Aldrich, M | 1 |
| Angelus, P | 1 |
| Zarfin, Y | 1 |
| Koren, G | 1 |
| Maresky, D | 1 |
| Perlman, M | 1 |
| MacLeod, S | 1 |
1 review available for gentamicin and Ductus Arteriosus, Patent
| Article | Year |
|---|---|
Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period.
Topics: Animals; Cimetidine; Ductus Arteriosus; Ductus Arteriosus, Patent; Gentamicins; Heparin; Histamine H | 2010 |
1 trial available for gentamicin and Ductus Arteriosus, Patent
| Article | Year |
|---|---|
Gentamicin pharmacokinetics in neonates with patent ductus arteriosus.
Topics: Anti-Bacterial Agents; Cohort Studies; Ductus Arteriosus, Patent; Gentamicins; Gestational Age; Huma | 1997 |
16 other studies available for gentamicin and Ductus Arteriosus, Patent
| Article | Year |
|---|---|
Relationship between Gentamicin Administration and Ductal Patency in Very Low Birth Weight Infants.
Topics: Ductus Arteriosus, Patent; Gentamicins; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, | 2022 |
Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Case-Control St | 2017 |
Patent Ductus Arteriosus with Infective Vegetations in Grandmultipara.
Topics: Adult; Aspirin; Ductus Arteriosus, Patent; Echocardiography; Endocarditis, Bacterial; Female; Fever; | 2018 |
Birth weight, Apgar scores and gentamicin were associated with acute kidney injuries in VLBW neonates requiring treatment for patent ductus arteriosus.
Topics: Acute Kidney Injury; Apgar Score; Birth Weight; Ductus Arteriosus, Patent; Female; Gentamicins; Huma | 2019 |
Standard-dose gentamicin does not increase risk of patent ductus arteriosus.
Topics: Animals; Animals, Newborn; Anti-Bacterial Agents; Ductus Arteriosus, Patent; Gentamicins; Rats; Rats | 2020 |
Aminoglycoside-mediated relaxation of the ductus arteriosus in sepsis-associated PDA.
Topics: Animals; Chemokine CXCL12; Ductus Arteriosus; Ductus Arteriosus, Patent; Gentamicins; Humans; In Vit | 2014 |
A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bacteremia; Coh | 2016 |
Prevalence and independent risk factors for hearing impairment among very low birth weight infants.
Topics: Anti-Bacterial Agents; Craniofacial Abnormalities; Diuretics; Ductus Arteriosus, Patent; Evoked Pote | 2017 |
Patent ductus arteriosus with infective endarteritis.
Topics: Adult; Ductus Arteriosus, Patent; Echocardiography, Doppler; Endarteritis; Enterococcus faecalis; Fe | 2010 |
Increased urinary podocytes following indomethacin suggests drug-induced glomerular injury.
Topics: Anti-Bacterial Agents; Cardiovascular Agents; Drug Therapy, Combination; Ductus Arteriosus, Patent; | 2012 |
Use of 4-mg/kg/24-hour empiric aminoglycoside dosing in preoperative neonates with congenital heart disease.
Topics: Alprostadil; Anti-Bacterial Agents; Critical Illness; Drug Administration Schedule; Ductus Arteriosu | 2012 |
Gentamicin pharmacokinetics in neonates with patent ductus arteriosus.
Topics: Anti-Bacterial Agents; Ductus Arteriosus, Patent; Gentamicins; Humans; Infant, Newborn | 1997 |
Once-daily gentamicin dosing in newborn infants.
Topics: Bacterial Infections; Clinical Protocols; Cohort Studies; Drug Administration Schedule; Ductus Arter | 1999 |
Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus.
Topics: Anti-Bacterial Agents; Chi-Square Distribution; Ductus Arteriosus; Ductus Arteriosus, Patent; Female | 2001 |
Effect of patent ductus arteriosus on gentamicin pharmacokinetics in very low birth weight (less than 1,500 g) babies.
Topics: Ductus Arteriosus, Patent; Gentamicins; Half-Life; Humans; Infant, Low Birth Weight; Infant, Newborn | 1987 |
Possible indomethacin-aminoglycoside interaction in preterm infants.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Creatinine; Diuresis; Drug Interactions; Ductus Ar | 1985 |